Takeda to Shell Out $2.4 Billion After 97% of Claimants Participate in Settlement

As of September 2015, 97% of potential claimants have signed up to receive a portion of the $2.3 billion settlement that was announced in April 2015 between Takeda Pharmaceuticals and plaintiffs claiming that Takeda’s diabetes drug Actos caused their bladder cancer.

In the process of attracting claimants, Takeda settled 7 of the 9 cases that had already gone to trial, in addition to several of the nearly 10,000 cases pending in state and federal courts. Claims stem from allegations that the Japanese pharmaceutical company concealed knowledge that Actos may cause patients to develop bladder cancer.